| scholarly article | Q13442814 |
| P2093 | author name string | Kabir Mody | |
| Pashtoon Murtaza Kasi | |||
| Jason Starr | |||
| Ali Roberts | |||
| Madiha Iqbal | |||
| P2860 | cites work | ??? | Q94720111 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| DNA methylation biomarkers for blood-based colorectal cancer screening | Q34727314 | ||
| Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 | ||
| Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients | Q36545624 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection | Q37715050 | ||
| Treatment strategy for early gastric cancer | Q37831620 | ||
| Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer | Q37960201 | ||
| Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids | Q38201710 | ||
| Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. | Q39838615 | ||
| Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer | Q40352469 | ||
| The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells | Q40437073 | ||
| Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency or microsatellite instability in patients with colorectal cancers | Q41598555 | ||
| The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. | Q50042439 | ||
| Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. | Q52674273 | ||
| HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. | Q53010792 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 400-406 | |
| P577 | publication date | 2019-06-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. | |
| P478 | volume | 10 |
Search more.